A description of our value creation strategy - 8 May 2024

 An introduction to Roquefort Therapeutics - 2 May 2024

Our CEO Ajan Reginald being interviewed by IG - 8 March 2023

Roquefort Therapeutics inks first strategic licensing deal with diagnostics firm Randox – 20 February 2023

Proactive One2One Investor Forum – 26 January 2023

Roquefort Therapeutics demonstrates safety in two antibody programmes – 24 January 2023

Our CEO lays out strategy for 2023 – 9 January 2023

Explaining the significance of our "very exciting" cancer drug study results – 11 October 2022

Proactive One2One Investor Forum – 6 October 2022

CEO Ajan Reginald discusses Roquefort Therapeutics with Jeremy Naylor at Momentous Events.

Dr Graham Robertson discussing encouraging Roquefort Therapeutics data on therapeutic antibodies targeting Midkine.

Dr Graham Robertson on the advantages of Roquefort Therapeutics’ diverse Midkine portfolio

Dr Graham Robertson talking about Roquefort Therapeutics’ innovative oligo drug program.